1. Home
  2. CASH vs EWTX Comparison

CASH vs EWTX Comparison

Compare CASH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • EWTX
  • Stock Information
  • Founded
  • CASH 1954
  • EWTX 2017
  • Country
  • CASH United States
  • EWTX United States
  • Employees
  • CASH N/A
  • EWTX N/A
  • Industry
  • CASH Major Banks
  • EWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASH Finance
  • EWTX Health Care
  • Exchange
  • CASH Nasdaq
  • EWTX Nasdaq
  • Market Cap
  • CASH 1.7B
  • EWTX 1.5B
  • IPO Year
  • CASH N/A
  • EWTX 2021
  • Fundamental
  • Price
  • CASH $76.40
  • EWTX $15.57
  • Analyst Decision
  • CASH Buy
  • EWTX Buy
  • Analyst Count
  • CASH 2
  • EWTX 9
  • Target Price
  • CASH $91.00
  • EWTX $39.89
  • AVG Volume (30 Days)
  • CASH 140.0K
  • EWTX 782.1K
  • Earning Date
  • CASH 10-22-2025
  • EWTX 08-07-2025
  • Dividend Yield
  • CASH 0.26%
  • EWTX N/A
  • EPS Growth
  • CASH 4.46
  • EWTX N/A
  • EPS
  • CASH 6.92
  • EWTX N/A
  • Revenue
  • CASH $733,796,000.00
  • EWTX N/A
  • Revenue This Year
  • CASH $18.96
  • EWTX N/A
  • Revenue Next Year
  • CASH $5.11
  • EWTX N/A
  • P/E Ratio
  • CASH $11.10
  • EWTX N/A
  • Revenue Growth
  • CASH 5.46
  • EWTX N/A
  • 52 Week Low
  • CASH $62.79
  • EWTX $10.60
  • 52 Week High
  • CASH $86.00
  • EWTX $38.12
  • Technical
  • Relative Strength Index (RSI)
  • CASH 44.69
  • EWTX 64.68
  • Support Level
  • CASH $77.33
  • EWTX $13.93
  • Resistance Level
  • CASH $79.13
  • EWTX $15.12
  • Average True Range (ATR)
  • CASH 2.00
  • EWTX 0.71
  • MACD
  • CASH 0.11
  • EWTX 0.10
  • Stochastic Oscillator
  • CASH 33.07
  • EWTX 90.29

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: